Healthcare products maker Allergan, Inc. (
) on Monday caught some further positive commentary from analysts
at Goldman Sachs.
The firm maintained its "Buy" rating on AGN and lifted its price
target from $99 to $106 ahead of the company's Research &
Development Day, which is slated for Wed., March 28. That new
target suggests a 13% upside to the stock's Friday closing price of
Goldman noted that R&D Day could intrigue investors with
"impressive pipeline breadth, several programs with potentially
very meaningful sales potential, and a large number of trials set
to complete in the 2011/2012 timeframe."
Allergan shares were mostly flat in premarket trading
The Bottom Line
Shares of Allergan (
) have a .21% dividend yield, based on last night's closing stock
price of $93.61. The stock has technical support in the $85-$90
price area. The stock is trading near all-time highs.
Allergan, Inc. (
) is not recommended at this time, holding a Dividend.com DARS™
Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the
Best Dividend Stocks
, as well as a detailed explanation of
our ratings system here
Created by Dividend.com